Hørsholm, Denmark, January 31, 2006 - LifeCycle Pharma A/S announced today that it has achieved promising clinical results in a Phase I study for its LCP-Tacro, a proprietary, once-daily tacrolimus tablet formulation. "Our Phase I study clearly demonstrates that LCP-Tacro has a sustained release profile, allowing it to be dosed once daily in contrast with the original version of tacrolimus (Prograf®) which must be administered twice daily," said Michael Beckert, MD., Chief Operating Officer at LifeCycle Pharma. "Based on these results, we will now move LCP-Tacro rapidly into pivotal clinical trials for organ transplantation. Our once-daily LCP-Tacro product offers a clear advantage to patients," Michael Beckert added.
